ArticleThe journal of allergy and clinical immunology. Global2025
Clinical factors predicting nemolizumab response in atopic dermatitis.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials.Dermatology and therapy · 2026Article
- Real-World, Single-Center Analysis of Cutaneous Adverse Events with Nemolizumab: Toward Safer and More Effective Use.Journal of clinical medicine · 2025Article
- IL-31/33 Axis in Atopic Dermatitis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor response to treatment. While serum IgE levels and baseline Eczema Area Severity Index (EASI) scores alone were not predictive, their combination with disease duration improved discrimination between responders and nonresponders. Disease duration, serum IgE levels, and baseline EASI scores can be useful to predict nemolizumab efficacy in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.